Xiao et al found that patients with positive c-MET expression had significantly shorter progression-free survival (PFS) and overall survival (OS) than those with negative expression.[3] However, there is a lack of extensive reports on the efficacy of savolitinib in patients with MET-amplified advanced gastric cancer. The gene discussed is MET; the disease is gastric cancer.